There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD14


Brief Information

Name:Monocyte differentiation antigen CD14
Target Synonym:CD14,CD14 Molecule,Myeloid Cell-Specific Leucine-Rich Glycoprotein,CD14 Antigen,Monocyte Differentiation Antigen CD14
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
Cat. No. Species Product Description Structure Purity Feature
CD4-H8228 Human Biotinylated Human CD14 Protein, His,Avitag™
CD4-H5252 Human Human CD14 Protein, Fc Tag
CD4-H5228 Human Human CD14 Protein, His Tag

Synonym Name



Cluster of differentiation 14 (CD14), is a cell surface glycoprotein, and is a is a component of the innate immune system. CD14 is a myelomonocytic differentiation antigen preferentially expressed on monocytes, macrophages, and activated granulocytes. CD14 exists in two forms. Either it is anchored into the membrane by a glycosylphosphatidylinositol tail (mCD14) or it appears in a soluble form (sCD14). Soluble CD14 either appears after shedding of mCD14 (48 kDa) or is directly secreted from intracellular vesicles (56 kDa). CD14 acts as a co-receptor (along with the Toll-like receptor TLR 4 and MD-2) for the detection of bacterial lipopolysaccharide (LPS). CD14 can bind LPS only in the presence of lipopolysaccharide-binding protein (LBP). CD14 has been proposed to be involved in various biological processes, including transportation of other lipids, cell-cell interaction during different immune responses, as well as recognition of apoptotic cells. Although LPS is considered its main ligand, CD14 also recognizes other pathogen-associated molecular patterns. CD14+ cells are monocytes that can differentiate into a host of different cells. CD14 has been shown to interact with Lipopolysaccharide-binding protein.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
IC-14 Phase 2 Clinical Icos Corporation Shock, Septic; Motor Neuron Disease; Pneumonia; Sepsis; Respiratory Distress Syndrome, Adult; Amyotrophic Lateral Sclerosis; Dengue; Acute Lung Injury Details

This web search service is supported by Google Inc.